Cetirizine Hydrochloride
FDA-approved product (tablet, oral), marketed as Cetirizine Hydrochloride, Cetirizine Hydrochloride Allergy, Cetirizine Hydrochloride Hives and 11 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Allergic conjunctivitis
- Allergic disease
- Allergic rhinitis
- Eye allergy
- Nasal congestion
- Pruritus
- Rhinitis, Allergic, Perennial
- Seasonal allergic rhinitis
- Urticaria
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Piperazine derivatives; Other antiallergics
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae26.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Cetirizine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pitavastatin SodiumExisting use: Abnormal circulating lipid concentration, Cardiovascular disease, Familial hypercholesterolemia and 2 more66.8% AI-predicted activityagainst M. tuberculosis18 registered studies
- AmisulprideExisting use: Nausea and vomiting, Post operative nausea and vomiting, Psychosis66.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ItraconazoleExisting use: Aspergillosis, Blastomycosis, Candidiasis and 4 more66.7% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Dantrolene SodiumExisting use: Cerebral palsy, Fever, Malignant hyperthermia and 4 more66.6% AI-predicted activityagainst M. tuberculosis12 registered studies
- LurbinectedinExisting use: Cancer, Neoplasm, Small cell lung carcinoma66.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Methixene HydrochlorideExisting use: Parkinson disease66.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- Cisapride MonohydrateExisting use: Gastrointestinal disease66.5% AI-predicted activityagainst M. tuberculosis5 registered studies
- Angiotensin Ii AcetateExisting use: Cardiovascular disease, Hypotension, Septic shock and 1 more66.3% AI-predicted activityagainst M. tuberculosis10 registered studies
- QuazepamExisting use: Insomnia66.3% AI-predicted activityagainst M. tuberculosis1 registered study
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more66.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TerconazoleExisting use: Triazole derivatives66.2% AI-predicted activityagainst M. tuberculosis10 registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma66.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Study of Bronchodilation Effects of Cetirizine
NCT01781507 · start 2011-06
Registered record
- Registry ID
- NCT01781507
- Conditions
- Allergic Rhinitis; Asthma
- Interventions
- Cetirizine; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2011-06
- Completion
- 2011-12
- Enrolment
- 21
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAllergic Rhinitis; AsthmaInterventionCetirizine; PlaceboPhasePhase 4Registry statusCompletedEfficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model
NCT01332188 · start 2011-04
Registered record
- Registry ID
- NCT01332188
- Conditions
- Allergic Conjunctivitis
- Interventions
- AC-170 0.05%; AC-170 0.1%; AC-170 0.24%; AC-170 0%
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2011-04
- Completion
- 2011-10
- Enrolment
- 101
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAllergic ConjunctivitisInterventionAC-170 0.05%; AC-170 0.1%; AC-170 0.24%; AC-170 0%PhasePhase 2 / Phase 3Registry statusCompletedRhinitis, Cognition and Driving Performance
NCT01318681 · start 2011-01
Registered record
- Registry ID
- NCT01318681
- Conditions
- Seasonal Allergic Rhinitis; Driving Ability; Cognition
- Interventions
- cetirizine 10 mg; fluticasone furoate; placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2011-01
- Completion
- 2012-10
- Enrolment
- 22
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSeasonal Allergic Rhinitis; Driving Ability; CognitionInterventioncetirizine 10 mg; fluticasone furoate; placeboPhaseNot applicableRegistry statusCompletedEfficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model
NCT01134328 · start 2010-05
Registered record
- Registry ID
- NCT01134328
- Conditions
- Allergic Conjunctivitis
- Interventions
- AC-150 Combo; AC-150A 0.1%; AC-150B 0.005%; Vehicle
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2010-05
- Completion
- 2010-07
- Enrolment
- 83
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAllergic ConjunctivitisInterventionAC-150 Combo; AC-150A 0.1%; AC-150B 0.005%; VehiclePhasePhase 2Registry statusCompletedIs Levocetirizine Less Sedating Than Cetirizine?
NCT00826943 · start 2009-01
Registered record
- Registry ID
- NCT00826943
- Conditions
- Allergic Rhinitis
- Interventions
- Cetirizine; Levocetirizine; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2009-01
- Completion
- 2009-05
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAllergic RhinitisInterventionCetirizine; Levocetirizine; PlaceboPhasePhase 4Registry statusCompletedAllergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo
NCT00851344 · start 2008-09
Registered record
- Registry ID
- NCT00851344
- Conditions
- Rhinitis, Allergic, Seasonal
- Interventions
- GSK835726 (10mg); GSK835726 (50mg); GSK835726 (100mg); Cetirizine (10mg); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2008-09
- Completion
- 2008-11
- Enrolment
- 54
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRhinitis, Allergic, SeasonalInterventionGSK835726 (10mg); GSK835726 (50mg); GSK835726 (100mg); Cetirizine (10mg) +1 morePhasePhase 2Registry statusCompletedPhase 1 Study of Levocetirizine
NCT02447393 · start 2008-03-18
Registered record
- Registry ID
- NCT02447393
- Conditions
- Dermatitis
- Interventions
- levocetirizine; cetirizine; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-03-18
- Completion
- 2008-04-30
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDermatitisInterventionlevocetirizine; cetirizine; placeboPhasePhase 1Registry statusCompletedComparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation in Children With Allergic Rhinitis
NCT00488176 · start 2007-04
Registered record
- Registry ID
- NCT00488176
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- montelukast; cetirizine; montelukast and cetirizine; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2007-04
- Completion
- 2013-12
- Enrolment
- 116
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSeasonal Allergic RhinitisInterventionmontelukast; cetirizine; montelukast and cetirizine; placeboPhasePhase 4Registry statusUnknownA Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Fasting Conditions
NCT00864279 · start 2006-08
Registered record
- Registry ID
- NCT00864279
- Conditions
- Healthy
- Interventions
- Cetirizine Hydrochloride 10 mg tablets, single dose; Zyrtec® 10 mg tablets, single dose
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2006-08
- Completion
- 2006-09
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionCetirizine Hydrochloride 10 mg tablets, single dose; Zyrtec® 10 mg tablets, single dosePhasePhase 1Registry statusCompletedStudy to Assess the Effect of a Combination of Cetirizine With Pseudoephedrine Versus Cetirizine Alone on Symptoms in Patients With Allergic Rhinitis
NCT00334698 · start 2006-07
Registered record
- Registry ID
- NCT00334698
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- Cetirizine; Pseudoephedrine; Cetirizine with Pseudoephedrine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2006-07
- Completion
- 2006-09
- Enrolment
- 51
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSeasonal Allergic RhinitisInterventionCetirizine; Pseudoephedrine; Cetirizine with PseudoephedrinePhaseNot applicableRegistry statusCompletedCetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fasting Condition
NCT01064102 · start 2006-01
Registered record
- Registry ID
- NCT01064102
- Conditions
- Healthy
- Interventions
- Cetirizine Hydrochloride
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2006-01
- Completion
- 2006-02
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionCetirizine HydrochloridePhasePhase 1Registry statusCompletedRandomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema
NCT00375713 · start 2005-10
Registered record
- Registry ID
- NCT00375713
- Conditions
- Dermatitis; Eczema
- Interventions
- Levocetirizine; Cetirizine; Placebo-Levocetirizine; Placebo-Cetirizine; Standard topical steroid (1% hydrocortisone) ointment
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-10
- Completion
- 2006-05
- Enrolment
- 466
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDermatitis; EczemaInterventionLevocetirizine; Cetirizine; Placebo-Levocetirizine; Placebo-Cetirizine +1 morePhasePhase 3Registry statusCompletedStudy Of Atopic Dermatitis In Pediatrics
NCT00257569 · start 2005-08
Registered record
- Registry ID
- NCT00257569
- Conditions
- Dermatitis, Atopic
- Interventions
- Cetirizine Dry Syrup
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-08
- Completion
- Not recorded
- Enrolment
- 278
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDermatitis, AtopicInterventionCetirizine Dry SyrupPhasePhase 3Registry statusCompletedEfficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis
NCT00504933 · start 2005-05
Registered record
- Registry ID
- NCT00504933
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- bilastine; Cetirizine; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-05
- Completion
- 2005-11
- Enrolment
- 683
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSeasonal Allergic RhinitisInterventionbilastine; Cetirizine; PlaceboPhasePhase 3Registry statusCompletedBioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fasting Conditions
NCT00776139 · start 2004-10
Registered record
- Registry ID
- NCT00776139
- Conditions
- Healthy
- Interventions
- Cetirizine Hydrochloride 10 mg tablet
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2004-10
- Completion
- 2004-12
- Enrolment
- 32
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionCetirizine Hydrochloride 10 mg tabletPhaseNot applicableRegistry statusCompleted